Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Novavax's Total Liabilities for the quarter that ended in Dec. 2023 was $2,514.4 Mil. Novavax's Total Assets for the quarter that ended in Dec. 2023 was $1,797.5 Mil.
Therefore, Novavax's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 was 1.40.
Novavax Liabilities-to-Assets Historical Data
The historical data trend for Novavax's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Novavax's Liabilities-to-Assets
For the Biotechnology subindustry, Novavax's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novavax's Liabilities-to-Assets Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Novavax's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Novavax's Liabilities-to-Assets falls into.
Novavax Liabilities-to-Assets Calculation
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Novavax's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Novavax Liabilities-to-Assets Related Terms
Thank you for viewing the detailed overview of Novavax's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NVAX has been successfully added to your 